University of Louisville ophthalmology professor receives $60,000 RPB Special Scholar Award

NewsGuard 100/100 Score

Qingxian Lu, PhD, assistant professor of ophthalmology and visual sciences at the University of Louisville School of Medicine, has received the $60,000 William and Mary Greve Special Scholar Award from the Research to Prevent Blindness (RPB) organization. The funds will go toward Lu's research in retinitis pigmentosa, a group of genetic disorders that can lead to night blindness, loss of peripheral vision and total blindness.

Lu's research focuses specifically on a cellular receptor called MerTK, which may play a role in limiting the duration of immune response, leading to the development of retinal inflammation. Understanding this mechanism of action may lead to better prevention and treatment techniques in the future.

Retinitis pigmentosa is a group of inherited disorders caused by molecular defects in more than 100 different genes. Navajo Indians are the ethnic group most affected by it.

"The RPB Special Scholar Award will significantly accelerate our ongoing research programs and secure a continuous investigation of the cellular activity related to the development of the retinal autoimmunity that occurs in retinitis pigmentosa," Lu said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Prime editing takes gene therapy to the next level